IDT Australia Executes API Development Agreement

• API Development Agreement executed with The State Government of Victoria • Total consideration over AUD 2,000,000 over the twelve month term of the project Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX:IDT) announces it…

Read More

Prima BioMed has just announced new clinical data from its TACTI-mel Phase I trial in Australia – which is investigating Prima’s lead drug, IMP321, in combination with KEYTRUDA in metastatic melanoma

Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial in Australia investigating the use of eftilagimod alpha (LAG-3Ig or IMP321), the Company’s lead…

Read More

Home

News & opinion

Member Directory

Events